三重再摄取抑制剂：前提与希望。
Triple reuptake inhibitors: a premise and promise.
机构信息
Department of Psychiatry, Duke University Medical Center, Durham, North Carolina, USA.
出版信息
Psychiatry Investig. 2008 Sep;5(3):142-7. doi: 10.4306/pi.2008.5.3.142. Epub 2008 Sep 30.
Abstract
On the horizon there is a new class of psychoactive medications which work by inhibiting the neuronal reuptake of serotonin, norepinephrine, and dopamine. There are multiple potential indications for these drugs. Research suggests that they may have a role in treating depressive disorders, and it is plausible they may have potential efficacy in obesity, addiction, and pain syndromes. The current review describes some of the molecules in development presently and explores the research relevant to possible clinical uses for this class of medications.
摘要
在视野中出现了一类新的精神活性药物，它们通过抑制神经元对 5-羟色胺、去甲肾上腺素和多巴胺的再摄取而起作用。这些药物有多种潜在的适应证。研究表明，它们可能在治疗抑郁障碍方面具有作用，而且在肥胖症、成瘾和疼痛综合征中也可能具有潜在的疗效。本综述描述了目前正在开发的一些分子，并探讨了与这类药物可能的临床用途相关的研究。
相似文献
1
Triple reuptake inhibitors: a premise and promise.
Psychiatry Investig. 2008 Sep;5(3):142-7. doi: 10.4306/pi.2008.5.3.142. Epub 2008 Sep 30.
2
Triple reuptake inhibitors: the next generation of antidepressants.
Curr Neuropharmacol. 2008 Dec;6(4):338-43. doi: 10.2174/157015908787386078.
3
Prospect of a dopamine contribution in the next generation of antidepressant drugs: the triple reuptake inhibitors.
Curr Drug Targets. 2009 Nov;10(11):1069-84. doi: 10.2174/138945009789735156.
4
Antidepressant-like effects of novel triple reuptake inhibitors, PRC025 and PRC050.
Eur J Pharmacol. 2007 Jan 19;555(1):30-6. doi: 10.1016/j.ejphar.2006.10.004. Epub 2006 Oct 17.
5
Triple uptake inhibitors: therapeutic potential in depression and beyond.
Expert Opin Investig Drugs. 2007 Sep;16(9):1365-77. doi: 10.1517/13543784.16.9.1365.
6
Triple reuptake inhibitors ("broad spectrum" antidepressants).
CNS Neurol Disord Drug Targets. 2007 Apr;6(2):141-9. doi: 10.2174/187152707780363285.
7
Development of potent dopamine-norepinephrine uptake inhibitors (DNRIs) based on a (2S,4R,5R)-2-benzhydryl-5-((4-methoxybenzyl)amino)tetrahydro-2H-pyran-4-ol molecular template.
Bioorg Med Chem. 2015 Feb 15;23(4):821-8. doi: 10.1016/j.bmc.2014.12.040. Epub 2014 Dec 25.
8
Effects of serotonin-norepinephrine reuptake inhibitors on locomotion and prefrontal monoamine release in spontaneously hypertensive rats.
Eur J Pharmacol. 2013 Feb 28;702(1-3):250-7. doi: 10.1016/j.ejphar.2013.01.033. Epub 2013 Jan 30.
9
Serotonin and Norepinephrine Reuptake Inhibitors.
Handb Exp Pharmacol. 2019;250:145-180. doi: 10.1007/164_2018_164.
10
Triple reuptake inhibitors: Design, synthesis and structure-activity relationship of benzylpiperidine-tetrazoles.
Bioorg Med Chem. 2017 Oct 15;25(20):5278-5289. doi: 10.1016/j.bmc.2017.07.046. Epub 2017 Jul 27.
引用本文的文献
1
A Pharmacogenomic-based Antidepressant Treatment for Patients with Major Depressive Disorder: Results from an 8-week, Randomized, Single-blinded Clinical Trial.
Clin Psychopharmacol Neurosci. 2018 Nov 30;16(4):469-480. doi: 10.9758/cpn.2018.16.4.469.
2
Pain and depression: a neurobiological perspective of their relationship.
Psychiatry Investig. 2015 Jan;12(1):1-8. doi: 10.4306/pi.2015.12.1.1. Epub 2015 Jan 12.
3
Vortioxetine: a meta-analysis of 12 short-term, randomized, placebo-controlled clinical trials for the treatment of major depressive disorder.
J Psychiatry Neurosci. 2015 May;40(3):174-86. doi: 10.1503/jpn.140120.
4
Discovery of novel-scaffold monoamine transporter ligands via in silico screening with the S1 pocket of the serotonin transporter.
ACS Chem Neurosci. 2014 Sep 17;5(9):784-92. doi: 10.1021/cn500133b. Epub 2014 Jul 15.
5
Treatment-resistant depression: therapeutic trends, challenges, and future directions.
Patient Prefer Adherence. 2012;6:369-88. doi: 10.2147/PPA.S29716. Epub 2012 May 1.
6
Aripiprazole as adjunctive therapy for patients with major depressive disorder: overview and implications of clinical trial data.
CNS Drugs. 2011 Feb;25(2):109-27. doi: 10.2165/11538980-000000000-00000.
本文引用的文献
1
Dopamine D2-like receptor in the nucleus accumbens is involved in the antinociceptive effect of nitrous oxide.
Anesth Analg. 2008 Jun;106(6):1904-9. doi: 10.1213/ane.0b013e318172b15b.
2
Effect of DOV 102,677 on the volitional consumption of ethanol by Myers' high ethanol-preferring rat.
Alcohol Clin Exp Res. 2007 Nov;31(11):1866-71. doi: 10.1111/j.1530-0277.2007.00513.x. Epub 2007 Sep 26.
3
Comprehensive analysis of remission (COMPARE) with venlafaxine versus SSRIs.
Biol Psychiatry. 2008 Feb 15;63(4):424-34. doi: 10.1016/j.biopsych.2007.06.027. Epub 2007 Sep 24.
4
Is there a common resilience mechanism underlying antidepressant drug response? Evidence from 2848 patients.
J Clin Psychiatry. 2007 Aug;68(8):1195-205. doi: 10.4088/jcp.v68n0805.
5
Duloxetine and other antidepressants in the treatment of patients with fibromyalgia.
Pain Med. 2007 Sep;8 Suppl 2:S63-74. doi: 10.1111/j.1526-4637.2006.00178.x.
6
Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents.
Biol Psychiatry. 2007 Dec 1;62(11):1217-27. doi: 10.1016/j.biopsych.2007.03.027. Epub 2007 Jun 22.
7
Effects of sibutramine and orlistat on mood in obese and overweight subjects: a randomised study.
Nutr Metab Cardiovasc Dis. 2008 Mar;18(3):207-10. doi: 10.1016/j.numecd.2006.10.003. Epub 2007 Jun 13.
8
Synthesis of enantiomerically pure milnacipran analogs and inhibition of dopamine, serotonin, and norepinephrine transporters.
Bioorg Med Chem Lett. 2007 May 15;17(10):2834-7. doi: 10.1016/j.bmcl.2007.02.054. Epub 2007 Feb 27.
9
Characterization of the antinociceptive actions of bicifadine in models of acute, persistent, and chronic pain.
J Pharmacol Exp Ther. 2007 Jun;321(3):1208-25. doi: 10.1124/jpet.106.116483. Epub 2007 Feb 26.
10
Randomized trial of the triple monoamine reuptake inhibitor NS 2330 (tesofensine) in early Parkinson's disease.
Mov Disord. 2007 Feb 15;22(3):359-65. doi: 10.1002/mds.21258.
Zotero 插件